Pfizer Inc. (BCBA:PFE)
Argentina · Delayed Price · Currency is ARS 7,860.00
-10.00 (-0.13%)
Jul 16, 2025, 4:38 PM BRT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Oncology | 15.61B | Log In | Log In | Log In | Log In | Upgrade |
Oncology Growth | 21.68% | Log In | Log In | Log In | Log In | Upgrade |
Other | 81.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 40.35% | Log In | Log In | Log In | Log In | Upgrade |
Business Innovation (Pfizer CentreOne) | 1.15B | Log In | Log In | Log In | Log In | Upgrade |
Business Innovation (Pfizer CentreOne) Growth | -6.22% | Log In | Log In | Log In | Log In | Upgrade |
Primary Care | 30.14B | Log In | Log In | Log In | Log In | Upgrade |
Primary Care Growth | 8.20% | Log In | Log In | Log In | Log In | Upgrade |
Specialty Care | 16.65B | Log In | Log In | Log In | Log In | Upgrade |
Specialty Care Growth | 10.40% | Log In | Log In | Log In | Log In | Upgrade |
Other | 81.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 40.35% | Log In | Log In | Log In | Log In | Upgrade |
Other | 81.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 40.35% | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | 24.94B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
United States | 38.69B | Log In | Log In | Log In | Log In | Upgrade |
United States Growth | 29.72% | Log In | Log In | Log In | Log In | Upgrade |
Developed Markets | 16.06B | Log In | Log In | Log In | Log In | Upgrade |
Developed Markets Growth | -13.19% | Log In | Log In | Log In | Log In | Upgrade |
Emerging Markets Revenue (Post-FY2023 Reporting) | 8.88B | Log In | Log In | Log In | Log In | Upgrade |
Emerging Markets Revenue (Post-FY2023 Reporting) Growth | 4.12% | Log In | Log In | Log In | Log In | Upgrade |
Other | 24.94B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Developed Europe | - | Log In | Log In | Log In | Log In | Upgrade |
Developed Europe Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Developed Rest of World | - | Log In | Log In | Log In | Log In | Upgrade |
Developed Rest of World Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Emerging Markets | - | Log In | Log In | Log In | Log In | Upgrade |
Emerging Markets Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | 24.94B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | -12.73B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 32.22% | Log In | Log In | Log In | Log In | Upgrade |
Other | -12.73B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 32.22% | Log In | Log In | Log In | Log In | Upgrade |
Global Pharmaceuticals Business (Biopharma) Earnings | 28.14B | Log In | Log In | Log In | Log In | Upgrade |
Global Pharmaceuticals Business (Biopharma) Earnings Growth | -6.78% | Log In | Log In | Log In | Log In | Upgrade |
Other Business Activities Earnings | -7.38B | Log In | Log In | Log In | Log In | Upgrade |
Other Business Activities Earnings Growth | -29.25% | Log In | Log In | Log In | Log In | Upgrade |
Other | -12.73B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 32.22% | Log In | Log In | Log In | Log In | Upgrade |
Prevnar Revenue | - | Log In | Log In | Log In | Log In | Upgrade |
Prevnar Revenue Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Xeljanz Revenue | 1.17B | Log In | Log In | Log In | Log In | Upgrade |
Xeljanz Revenue Growth | -33.57% | Log In | Log In | Log In | Log In | Upgrade |
Vaccines Revenue | - | Log In | Log In | Log In | Log In | Upgrade |
Vaccines Revenue Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Ibrance Revenue | 4.37B | Log In | Log In | Log In | Log In | Upgrade |
Ibrance Revenue Growth | -8.02% | Log In | Log In | Log In | Log In | Upgrade |
Internal Medicine Revenue | - | Log In | Log In | Log In | Log In | Upgrade |
Internal Medicine Revenue Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Inflammation & Immunology Revenue | - | Log In | Log In | Log In | Log In | Upgrade |
Inflammation & Immunology Revenue Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Rare Disease Revenue | - | Log In | Log In | Log In | Log In | Upgrade |
Rare Disease Revenue Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Eliquis Alliance Revenue and Direct Sales | 7.37B | Log In | Log In | Log In | Log In | Upgrade |
Eliquis Alliance Revenue and Direct Sales Growth | 4.88% | Log In | Log In | Log In | Log In | Upgrade |
Vyndaqel Family Revenue | 5.45B | Log In | Log In | Log In | Log In | Upgrade |
Vyndaqel Family Revenue Growth | 53.76% | Log In | Log In | Log In | Log In | Upgrade |
Hospital Revenue | - | Log In | Log In | Log In | Log In | Upgrade |
Hospital Revenue Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Comirnaty Direct Sales and Alliance Revenue | 5.35B | Log In | Log In | Log In | Log In | Upgrade |
Comirnaty Direct Sales and Alliance Revenue Growth | -34.60% | Log In | Log In | Log In | Log In | Upgrade |
Paxlovid Revenue | 5.72B | Log In | Log In | Log In | Log In | Upgrade |
Paxlovid Revenue Growth | -652.58% | Log In | Log In | Log In | Log In | Upgrade |
Prevnar Family Revenue | 6.41B | Log In | Log In | Log In | Log In | Upgrade |
Prevnar Family Revenue Growth | -3.17% | Log In | Log In | Log In | Log In | Upgrade |
Nurtec ODT/Vydura Revenue | 1.26B | Log In | Log In | Log In | Log In | Upgrade |
Nurtec ODT/Vydura Revenue Growth | 41.81% | Log In | Log In | Log In | Log In | Upgrade |
Abrysvo Revenue | 755.00M | Log In | Log In | Log In | Log In | Upgrade |